STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery Disease
(MedPage Today) — CHICAGO — Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major…
Review links 3 potentially-blinding eye conditions to GLP-1 drugs like Ozempic
Post Content
Can drugs like Ozempic help with COPD?
Post Content
Ozempic, Wegovy may help curb alcohol cravings
Post Content
Federal judge denies preliminary injunction in tirzepatide compounding case
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide from its official shortage list.
The US District Court for the Northern District of Texas denied …
Novo Nordisk’s Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more…
Ozempic is increasingly being linked to vision loss. What’s the truth?
Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why
Makers of Wegovy and Zepbound cut prices for those without insurance
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance.
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 — The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Novo Nordisk, the Danish company behind Wegovy…
Is Intermittent Fasting Worth Considering for Your Patients?
Studies suggest types of fasting can lead to moderate weight loss and other health benefits in overweight and obese people, but only some doctors use it. Medscape Medical News